No Data
No Data
Taiko Pharmaceutical Raises FY Net View to Y550.00M
GROUP New Forecast Prior For Year To Dec 2024 Forecast Revenue Y6.80 bln Y6.80 bln Operating Profit Y410.00 mln
Taiko Pharmaceutical Sees FY Net Y350.00M
Taiko Pharmaceutical Co. Ltd. also released the following forecasts: GROUP Year Ending Dec 2024 Revenue Y6.80 bln Operating Profit Y410.00 mln Pre
Taiko Pharmaceutical FY Loss Y3.61B Vs Loss Y4.90B
Taiko Pharmaceutical Co. Ltd. (4574.TO) Japan Year Ended December 31 GROUP 2023 2022 Revenue Y6.12 bln Y5.04 bln Operating Profit (Y1.01 bln
Taiko Pharmaceutical 9-Mos Loss Y562.00M Vs Loss Y3.18B
Taiko Pharmaceutical Co. Ltd. (4574.TO) Japan Nine Months Ended September 30 GROUP 2023 2022 Revenue Y4.42 bln Y3.39 bln Operating Profit
Kingworld Medicines Subsidiary Buys Shares in Taiko Pharmaceutical
Kingworld Medicines Group (HKG:1110) subsidiary Kingworld Medicines Health Management purchased an additional 1,007,500 shares in Japan-based Taiko Pharmaceutical (TYO:4574) at 338.58 yen per share, a
Jinhuo Pharmaceutical Group (01110.HK): Further subscription for shares in Taiko Pharmaceutical
On August 16, 2023, Goldwell Pharmaceutical Group (01110.HK) issued an announcement. On August 15, 2023, Jinhuo Pharmaceutical, a wholly-owned subsidiary of the company, placed an order with the distribution agent. Based on this, Jinhuo Pharmaceutical agreed to subscribe for an additional 1.075 million Taiko shares at a cost of 338.58 yen (equivalent to about HK$18.35) per share of Taiko Shares (accounting for about 2.08% of Taiko Pharmaceutical's issued share capital as of the date of this announcement, excluding Taiko Pharmaceutical After completion, according to the subscription details
No Data